Drug
Beam 302
Beam 302: highest development phase Phase 1/2, developed by Beam Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Beam Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| BEAM-302 NCT06389877 | Phase 1/2 | Alpha 1-Antitrypsin Deficiency |
Latest
No recent events.
Follow Beam 302 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.